MedPath

Iohexol

Generic Name
Iohexol
Brand Names
Omnipaque, Oraltag
Drug Type
Small Molecule
Chemical Formula
C19H26I3N3O9
CAS Number
66108-95-0
Unique Ingredient Identifier
4419T9MX03
Background

Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.

Indication

Iohexol ia used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures.

Clinical Trials
Related News

Optimization of Beta-lactam Dosing in Critically Ill Patients With Cystatin C (OPTIMIZE-GNI)

Phase 4
Recruiting
Conditions
Bacterial Infection
Interventions
First Posted Date
2024-11-29
Last Posted Date
2025-04-18
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
150
Registration Number
NCT06709521
Locations
🇺🇸

Harbor UCLA Medical Center - Medicine - Infectious Diseases, Torrance, California, United States

🇺🇸

Torrance Memorial Medical Center, Torrance, California, United States

🇺🇸

Henry Ford Health System - Henry Ford Hospital, Detroit, Michigan, United States

and more 7 locations

Method VALIDation and Evaluation of Non-radioactive Methods to Measure Glomerular Filtration Rate

Not Applicable
Not yet recruiting
Conditions
Chronic Kidney Diseases
Kidney Function Issue
Diagnosis
Interventions
Diagnostic Test: 125I-iothalamate and 131I-hippuran
First Posted Date
2024-02-14
Last Posted Date
2024-03-13
Lead Sponsor
University Medical Center Groningen
Target Recruit Count
208
Registration Number
NCT06259422
Locations
🇳🇱

University Medical Centre Groningen, Groningen, Netherlands

Neoadjuvant Therapy and Contrast-enhanced Mammography for Early Stage Breast Cancer

Early Phase 1
Recruiting
Conditions
TNBC, Triple Negative Breast Cancer
HER2-positive Breast Cancer
Breast Cancer
Locally Advanced Breast Cancer
Neoadjuvant Chemotherapy
Triple Negative Breast Cancer
Interventions
Diagnostic Test: CEDM
Diagnostic Test: CEDBT
First Posted Date
2024-01-23
Last Posted Date
2024-03-07
Lead Sponsor
Alison Stopeck
Target Recruit Count
30
Registration Number
NCT06220214
Locations
🇺🇸

Stony Brook Breast Center, Stony Brook, New York, United States

Chest CT Using Low-concentration Iodine Contrast Media

First Posted Date
2023-08-01
Last Posted Date
2024-07-25
Lead Sponsor
Jung Im Jung
Target Recruit Count
370
Registration Number
NCT05967117
Locations
🇰🇷

Bucheon St. Mary's Hospital, The Catholic University of Korea, Bucheon, Gyeonggi-do, Korea, Republic of

🇰🇷

Pusan National University Yangsan Hospital, Yangsan, Gyeongsangnam-do, Korea, Republic of

🇰🇷

Seoul National University Hospital, Seoul, Korea, Republic of

and more 3 locations

Ultrasound-guided LMBB by Caudal-cranial Approach: Radiographic Comparison of a New Ultrasound-guided Method

Not Applicable
Recruiting
Conditions
Chronic Low-back Pain
Lumbar Facet Joint Syndrome
Interventions
Diagnostic Test: Lumbar medial branch block
Drug: Lidocain
First Posted Date
2023-07-05
Last Posted Date
2023-07-05
Lead Sponsor
Erasme University Hospital
Target Recruit Count
40
Registration Number
NCT05930236
Locations
🇧🇪

Hôpital Erasme, Bruxelles, Belgium

Comparison of CE-DBT and MRI in Patients With Known Breast Lesions

Early Phase 1
Recruiting
Conditions
Breast Cancer
Interventions
First Posted Date
2023-03-06
Last Posted Date
2024-11-22
Lead Sponsor
UNC Lineberger Comprehensive Cancer Center
Target Recruit Count
20
Registration Number
NCT05754749
Locations
🇺🇸

University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States

A Study of Effect of LY3556050 on Metformin in Healthy Participants

Phase 1
Completed
Conditions
Healthy
Interventions
First Posted Date
2022-11-14
Last Posted Date
2023-01-18
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
18
Registration Number
NCT05615467
Locations
🇺🇸

PRA International, Salt Lake City, Utah, United States

A Study of LY3526318 in Healthy Male Japanese Participants

Phase 1
Withdrawn
Conditions
Healthy
Interventions
Drug: Placebo
First Posted Date
2022-10-14
Last Posted Date
2023-01-09
Lead Sponsor
Eli Lilly and Company
Registration Number
NCT05580250
Locations
🇯🇵

Souseikai Fukuoka Mirai Hospital, Fukuoka, Japan

Renal Hemodynamics, Energetics and Insulin Resistance: A Follow-up Study

Conditions
Type 2 Diabetes
Diabetic Nephropathies
Adolescent Obesity
Diabetic Kidney Disease
Nephropathy
Obesity
Diabetes Type 2
Interventions
Procedure: Renal Biopsy
Radiation: Positron Emission Tomography
First Posted Date
2022-09-07
Last Posted Date
2022-11-02
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
100
Registration Number
NCT05530356
Locations
🇺🇸

Children's Hospital Colorado, Aurora, Colorado, United States

Hormone Therapy and Angiotensin-Dependent Arterial and Renal Vasoconstriction in Humans

Recruiting
Conditions
Hormone Therapy
Interventions
First Posted Date
2022-07-05
Last Posted Date
2025-03-27
Lead Sponsor
University of Calgary
Target Recruit Count
200
Registration Number
NCT05442463
Locations
🇨🇦

University of Calgary, Calgary, Alberta, Canada

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy